Microbial Features Linked to Medication Strategies in Cardiometabolic Disease Management.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
received:
29
09
2023
revised:
05
01
2024
accepted:
15
01
2024
pmc-release:
05
02
2025
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
26
4
2024
Statut:
epublish
Résumé
Human gut microbiota are recognized as critical players in both metabolic disease and drug metabolism. However, medication-microbiota interactions in cardiometabolic diseases are not well understood. To gain a comprehensive understanding of how medication intake impacts the gut microbiota, we investigated the association of microbial structure with the use of single or multiple medications in a cohort of 134 middle-aged adults diagnosed with cardiometabolic disease, recruited from Alberta's Tomorrow Project. Predominant cardiometabolic prescription medication classes (12 total) were included in our analysis. Multivariate Association with Linear Model (
Identifiants
pubmed: 38665607
doi: 10.1021/acsptsci.3c00261
pmc: PMC11040554
doi:
Types de publication
Journal Article
Langues
eng
Pagination
991-1001Informations de copyright
© 2024 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.